## Committed to Patients. Driven to Discover.

At Bristol Myers Squibb, we are driven by the discovery of science that may transform the lives of cancer patients.

Until we can meet again, please explore our oncology early stage disease pipeline below.



## Oncology Early Stage Disease Pipeline

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. There is no guarantee that investigational agents or investigational uses will receive health authority approval or become commercially available in any country. Information as of March 2021.

Breast  (iii) Nevalumab + CDK inhibition + anomalose inhibitor anomalose inhibitor anomalose inhibitor + anoma		Modality	Area of Research	Phase
Continibitor + aromatose inhibitor followed by noolumab + CDK inhibitor + aromatose inhibitor followed by anti-PD-1 + CDK inhibitor + aromatose inhibitor followed by anti-PD-1 + CDK inhibitor + aromatose inhibitor followed by anti-PD-1 + CDK inhibitor + aromatose inhibitor followed by anti-PD-1 + CDK inhibitor + aromatose inhibitor followed by anti-PD-1 + CDK inhibitor + aromatose inhibitor followed by anti-PD-1 + Anti-PD-1 + Adjuvant esophageal or GEJ cancer 3    Anti-PD-1	Breast			
inhibitor followed by inhibitor - aromatase inhibitor atomatase in	Nivolumab + CDK inhibitor + aromatase inhibitor		Neoadjuvant ER+/HER2- breast cancer	2
Gastrointestinal Nivolumab Anti-PD-1 Adjuvant esophageal ar GEJ cancer  3 Nivolumab Anti-PD-1 Adjuvant HCC 3 Nivolumab + bempegaldesleukin (NKTR-214) Nivolumab + chema + linradostat mesylate Nivolumab + chema + linradostat mesylate Nivolumab + pplinumab Anti-PD-1 + cD122-biased Nivolumab + pplinumab Anti-PD-1 + inD01 inhibitor Peri-aperative MIBC 3 Nivolumab + pplinumab Anti-PD-1 + anti-CTLA-4 Adjuvant invasive high-risk urathelial corrinoma Anti-PD-1 ± anti-CTLA-4 Adjuvant RCC 3  Lung  © Neoadjuvant nivolumab + chema, followed by adjuvant nivolumab + chema, followed by adjuvant nivolumab Anti-PD-1 Resectable stage II-IIIB NSCLC (24cm)  Welanoma Nivolumab Ni		inhibitor followed by anti-PD-1 + CDK inhibitor +	Neoadjuvant ER+/HER2- breast cancer	2
Nivolumab  Anti-PD-1  Anti-PD-1  Adjuvant esophageal or GEJ cancer  3  Nivolumab  Anti-PD-1  Adjuvant fully resected stage  IlB/C melanoma  Nivolumab ± bempegoldesleukin (NKTR-214)  Anti-PD-1  Anti-PD-1  Adjuvant fully resected stage  IlB/C melanoma  Nivolumab ± bempegoldesleukin (NKTR-214)  Anti-PD-1  Anti-PD-1  Adjuvant fully resected melanoma in preferential II-2 pathway potients at high risk for recurrence		Anti–PD-1		3
Nivolumab   Anti-PD-1   Adjuvant HCC   3	Gastrointestinal			
Genitourinary  © Nivolumab ± bempegaldesleukin (NKTR-214) Anti–PD-1 ± CD122-biased IL-2 receptor  Nivolumab + chemo ± linrodostat mesylate Anti–PD-1 ± 1D01 inhibitor Anti–PD-1 Adjuvant invasive high-risk urothelial carcinoma Anti–PD-1 ± anti–CTLA-4 Adjuvant RCC  S  Lung  © Neoadjuvant nivolumab + chemo, followed by adjuvant nivolumab + chemo Anti–PD-1 Resectable stage II-IIIB NSCLC (24cm)  © Neoadjuvant nivolumab + chemo Anti–PD-1 Resectable stage IB-IIIA NSCLC (31 (24cm) Anti–PD-1 Resectable stage IB-IIIA NSCLC (31 (24cm) Anti–PD-1 Adjuvant fully resected stage IIB/C melanoma Nivolumab Nivolumab ± bempegaldesleukin (NKTR-214) Anti–PD-1 ± CD122- preferential IL-2 pathway Pottents at high risk for recurrence	Nivolumab	Anti–PD-1	Adjuvant esophageal or GEJ cancer	3
	Nivolumab	Anti–PD-1	Adjuvant HCC	3
IL-2 receptor  Nivolumab + chemo ± linrodostat mesylate  Anti–PD-1 ± IDO1 inhibitor  Peri-operative MIBC  3  Nivolumab  Anti–PD-1  Adjuvant invasive high-risk urathelial carcinoma  Nivolumab ± ipilimumab  Anti–PD-1 ± anti–CTLA-4  Adjuvant RCC  3  Lung  Neoadjuvant nivolumab + chemo, followed by adjuvant nivolumab  Anti–PD-1  Resectable stage II-IIIB NSCLC (24cm)  Neoadjuvant nivolumab + chemo  Anti–PD-1  Resectable stage IB-IIIA NSCLC (24cm)  Nivolumab  Nivolumab  Anti–PD-1  Adjuvant fully resected stage  IIB/C melanoma  Nivolumab ± bempegaldesleukin (NKTR-214)  Anti–PD-1 ± CD122- preferential IL-2 pathway patients at high risk for recurrence	Genitourinary			
Nivolumab Nivolumab ± ipilimumab Nivolumab ± ipilimumab  Anti-PD-1 ± anti-CTLA-4 Adjuvant RCC  3  Lung  Neoadjuvant nivolumab + chemo, followed by adjuvant nivolumab Anti-PD-1 Anti-PD-1 Resectable stage II-IIIB NSCLC (24cm)  Neoadjuvant nivolumab + chemo Anti-PD-1 Resectable stage IB-IIIA NSCLC (24cm)  Melanoma Nivolumab Nivolumab Anti-PD-1 Adjuvant fully resected stage IIB/C melanoma IIB/C melanoma Nivolumab ± bempegaldesleukin (NKTR-214) Anti-PD-1 ± CD122- preferential IL-2 pathway Preferential IL-2 pathway Preferential rich pathway Adjuvant fully resected melanoma in patients at high risk for recurrence	Nivolumab ± bempegaldesleukin (NKTR-214)		Peri-operative MIBC	3
Nivolumab ± ipilimumab  Anti–PD-1 ± anti–CTLA-4  Adjuvant RCC  3  Lung  Neoadjuvant nivolumab + chemo, followed by adjuvant nivolumab + chemo Neoadjuvant nivolumab + chemo Anti–PD-1  Resectable stage II-IIIB NSCLC (24cm)  Resectable stage IB-IIIA NSCLC (24cm)  Melanoma  Nivolumab  Anti–PD-1  Anti–PD-1  Adjuvant fully resected stage IIB/C melanoma  Nivolumab ± bempegaldesleukin (NKTR-214)  Anti–PD-1 ± CD122- preferential IL-2 pathway Potients at high risk for recurrence	Nivolumab + chemo ± linrodostat mesylate	Anti–PD-1 ± ID01 inhibitor	Peri-operative MIBC	3
Lung  Neoadjuvant nivolumab + chemo, followed by adjuvant nivolumab + chemo Neoadjuvant nivolumab + chemo Anti-PD-1 Resectable stage II-IIIB NSCLC (24cm)  Resectable stage IB-IIIA NSCLC (24cm)  Melanoma Nivolumab Anti-PD-1 Adjuvant fully resected stage IB-IIIA NSCLC (24cm)  Nivolumab Anti-PD-1 Adjuvant fully resected stage IB-IIIA NSCLC (24cm)  Nivolumab ± bempegaldesleukin (NKTR-214) Anti-PD-1 ± CD122- preferential IL-2 pathway patients at high risk for recurrence	Nivolumab	Anti–PD-1		3
	Nivolumab ± ipilimumab	Anti-PD-1 ± anti-CTLA-4	Adjuvant RCC	3
adjuvant nivolumab  Neoadjuvant nivolumab + chemo  Anti–PD-1  Resectable stage IB-IIIA NSCLC (≥4cm)  Melanoma  Nivolumab  Anti–PD-1  Adjuvant fully resected stage IIB/C melanoma  Nivolumab ± bempegaldesleukin (NKTR-214)  Anti–PD-1 ± CD122- preferential IL-2 pathway  Adjuvant fully resected melanoma in patients at high risk for recurrence	Lung			
Melanoma  Nivolumab  Anti−PD-1  Adjuvant fully resected stage IIB/C melanoma  ■ Nivolumab ± bempegaldesleukin (NKTR-214)  Anti−PD-1 ± CD122- Adjuvant fully resected melanoma in preferential IL-2 pathway patients at high risk for recurrence		Anti–PD-1		3
Nivolumab  Anti-PD-1  Adjuvant fully resected stage IIB/C melanoma  Nivolumab ± bempegaldesleukin (NKTR-214)  Anti-PD-1 ± CD122- preferential IL-2 pathway  Patients at high risk for recurrence		Anti–PD-1	_	3
IIB/C melanoma  O Nivolumab ± bempegaldesleukin (NKTR-214)  Anti–PD-1 ± CD122- preferential IL-2 pathway  patients at high risk for recurrence	Melanoma			
preferential IL-2 pathway patients at high risk for recurrence	Nivolumab	Anti–PD-1		3
	Nivolumab ± bempegaldesleukin (NKTR-214)	preferential IL-2 pathway		3

Trial investigates BMS agent(s) in combination with 1 or more non-BMS-owned assets. Development partnerships include:
 Bempegaldesleukin: Nektar

RCC=renal cell carcinoma; NSCLC=non-small cell lung cancer; PD-1=programmed death receptor-1

CDK=cyclin-dependent kinase; chemo=chemotherapy; CTLA-4=cytotoxic T-lymphocyte antigen 4; ER=estrogen receptor; ID01=indoleamine 2,3- deoxygenate-1; GEJ=gastroesophageal junction; HCC=hepatocellular carcinoma; HER2=human epidermal growth factor receptor 2: IL-2=interleukin-2; MIBC=muscle-invasive bladder cancer;

